Comdale, Of course all shareholders should be cross. BTA executives failed to show any PR skills - instead the CEO displayed exceptional skills in talking down the sp.
Instead of demanding GSK markets and promotes Relenza, BTA shareholders are told to expect Relenza to drop from the mainstream media headlines.
These are the rewards from the normalised relationship Peter Cook obtained for shareholders.
How dare shareholders expect GSK or BTA to promote Relenza.
BTA Price at posting:
$1.03 Sentiment: Sell Disclosure: Not Held
